|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,400 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: RECLAST
Summary for Tradename: RECLAST
|
| Pharmacology for Tradename: RECLAST
| ||||||||||||
Clinical Trials for: RECLASTPerioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer Status: Active, not recruiting Condition: Adenocarcinoma Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid Status: Active, not recruiting Condition: Breast Cancer PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer Status: Active, not recruiting Condition: Prostate Cancer Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy Status: Completed Condition: Prostate Cancer Re-treatment of Patients With Paget's Disease Using Zoledronic Acid Status: Completed Condition: Paget's Disease of the Bone Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year Status: Completed Condition: Multiple Myeloma; Breast Cancer The Use of Zoledronic Acid to Complex Regional Pain Syndrome Status: Not yet recruiting Condition: Complex Regional Pain Syndromes Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis Status: Completed Condition: Osteoporosis Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis Status: Completed Condition: Metastatic Breast Cancer; Bone Metastases Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901) Status: Recruiting Condition: Mesothelioma Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | RECLAST | zoledronic acid | INJECTABLE; IV (INFUSION) | 021817 | Apr 16, 2007 | RX | Yes | 4,939,130*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novartis | RECLAST | zoledronic acid | INJECTABLE; IV (INFUSION) | 021817 | Apr 16, 2007 | RX | Yes | 7,932,241*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novartis | RECLAST | zoledronic acid | INJECTABLE; IV (INFUSION) | 021817 | Apr 16, 2007 | RX | Yes | 8,052,987 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: RECLAST
| Drugname | Dosage | Strength | RLD | Submissiondate |
| zoledronic acid | Injection | 0.05 mg/mL, 100 mL vial | Reclast | 8/29/2008 |
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc
